Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0ECIBA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
YL-211
|
|||||
| Synonyms |
YL-211; YL 211; YL211
Click to Show/Hide
|
|||||
| Organization |
Roche Holding AG
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 1 Indication(s)
|
|||||
| Drug-to-Antibody Ratio |
8
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
YL0010014
|
Payload Info | ||||
| Therapeutic Target |
DNA topoisomerase 1 (TOP1)
|
Target Info | ||||
| Linker Name |
Tumor microenviroment activable tripeptide linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
B81
|
|||||
